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2013, accepted Nohe goal of this study was to review the prognostic value of cardiac magnetic resonance (CMR) imaging ﬁndings for
future cardiovascular events in patients with a recent myocardial infarction (MI) and patients with suspected or
known coronary artery disease (CAD). Although the diagnostic value of CMR ﬁndings is established, the independent
prognostic association with future cardiovascular events remains largely unclear. Studies published by February
2013, identiﬁed by systematic MEDLINE and EMBASE searches, were reviewed for associations between CMR
ﬁndings (left ventricular ejection fraction [LVEF], wall motion abnormalities [WMA], abnormal myocardial perfusion,
microvascular obstruction, late gadolinium enhancement, edema, and intramyocardial hemorrhage) and hard
events (all-cause mortality, cardiac death, cardiac transplantation, and MI) or major adverse cardiovascular events
(MACE) (hard events and other cardiovascular events deﬁned by the authors of the evaluated papers). Fifty-six
studies (n ¼ 25,497) were evaluated. For patients with recent MI, too few patients were evaluated to establish
associations between CMR ﬁndings and hard events. LVEF (range of adjusted hazard ratios [HRs]: 1.03 to 1.05 per %
decrease) was independently associated with MACE. In patients with suspected or known CAD, WMA (adjusted HRs:
1.87 to 2.99), inducible perfusion defects (adjusted HRs: 3.02 to 7.77), LVEF (adjusted HRs: 0.72 to 0.82 per 10%
increase), and infarction (adjusted HRs: 2.82 to 9.43) were independently associated with hard events, and the
presence of inducible perfusion defects was associated with MACE (adjusted HRs: 1.76 to 3.21). The independent
predictor of future cardiovascular events for patients with a recent MI was LVEF, and the predictors for patients with
suspected or known CAD were WMA, inducible perfusion defects, LVEF, and presence of infarction. (J Am Coll
Cardiol 2014;63:1031–45) ª 2014 by the American College of Cardiology FoundationDespite advances in prevention, detection, and treatment
in the last decades, coronary artery disease (CAD) remains a
leading cause of morbidity and mortality in the Western
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vember 26, 2013.computed tomography, and cardiac magnetic resonance
(CMR) imaging have rapidly evolved and are increasingly
used for diagnosis and treatment planning in patients with
recent myocardial infarction (MI) and suspected or known
CAD (2–4).See page 1046CMR is a comprehensive and accurate imaging modality
that combines anatomic information with dynamic assess-
ment of cardiac function. Advantages of CMR over other
imaging modalities include high spatial and temporal reso-
lution, the possibility to identify patients with ischemic heart
disease in 1 single examination, and absence of ionizing
radiation. Furthermore, CMR is considered the current
reference standard for the assessment of ventricular function
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1032and myocardial ﬁbrosis using late
gadolinium enhancement (LGE)
(5,6). In addition, CMR is able
to assess myocardial viability
and ischemia. CMR viability
imaging can be performed using
low-dose dobutamine, LGE scar
imaging, or a combination of both.
Myocardial wall motion imaging
during infusion of dobutamine
and perfusion imaging during
vasodilator administration are 2
CMR techniques to assess the
presence of myocardial ischemia.
The diagnostic performance of
CMR for detection of myocar-
dial ischemia and viability has
been well investigated (7–9).
Besides being an important
diagnostic tool, CMR may also
provide prognostic information.
However, data on prognosis fromindividual studies are limited, most often because of small
sample sizes and/or the low number of events in these
studies. Furthermore, the relative prognostic value of the
available CMR imaging ﬁndings is unclear. Given this un-
certainty, we performed a systematic review of studies
reporting prognostic data from patients undergoing CMR.
We speciﬁcally aimed to identify those CMR ﬁndings that
provide the best incremental prognostic information.Methods
Literature search strategy. We performed a comprehen-
sive systematic literature search in the MEDLINE and
EMBASE electronic databases on the February 25, 2013.
The search syntax included synonyms for CMR imaging
ﬁndings, combined with synonyms for the population of
interest (i.e., patients with recent MI within 2 weeks, and
suspected or known CAD), and a validated list of synonyms
to retrieve prognostic studies (Table 1) (10). We applied no
restrictions on publication date and language. Duplicate
papers were manually removed from the search results.
Selection of papers. Two authors (H.A. and A.A.) inde-
pendently double screened all titles and abstracts, and they
excluded papers on the basis of pre-deﬁned criteria. Dis-
agreements were resolved in a consensus review. An over-
view of the selection procedure is shown in Figure 1.
Reasons for exclusion of papers on the basis of title or ab-
stract were: 1) nonoriginal data (e.g., reviews, editorials,
guidelines, and comments); 2) nonclinical data (e.g., tech-
nical, animal, or in vitro studies); 3) case reports (e.g., studies
including <10 patients); 4) study populations investigated
for clinical indications other than recent MI and suspected
or known CAD; 5) studies that did not describe CMR
ﬁndings of interest; and 6) studies with patients who werenot followed up for cardiovascular events. The full text of the
remaining papers was reviewed for information on the
prognostic value of CMR imaging ﬁndings. Furthermore,
studies were excluded if: 1) only patients with a speciﬁc
result on CMR or other imaging results were included (e.g.,
only patients with wall motion abnormalities [WMA] on
echocardiography were selected); 2) follow-up was only
performed in a subgroup of patients deﬁned by the result of
CMR imaging (i.e., only patients with a positive or negative
CMR result); 3) no association between CMR ﬁnding of
interest and cardiovascular events was described; 4) CMR
was used to evaluate treatment and not for prognostication;
and 5) only patients with a low suspicion of CAD were
included. (Low suspicion of CAD was deﬁned as studies
that only included patients with chest pain without elec-
trocardiographic abnormalities and/or without negative
cardiac enzymes, because those patients are generally
considered to not be appropriate candidates for CMR [11].)
All references included in the remaining papers were
reviewed to retrieve papers initially missed in the original
search syntax.
Assessment of methodological quality. This systematic
review complies with the preferred reporting items of
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) (12). In contrast to randomized
controlled trials and diagnostic studies, there are no criteria for
quality appraisal of prognostic studies. We therefore adapted
a quality scale from validated scales for other types of clinical
studies and previously developed criteria for prognostic
factor studies, and addressed study quality on all domains
(13,14). To assess the quality of data analysis, reporting on
treatment of continuous data, prognostic model building stra-
tegies, and number of predictors per event were recorded (15).
Data extraction and analysis. A standardized form was
used to extract study data, including a description of the
study population, CMR imaging ﬁndings, patient charac-
teristics, cardiovascular risk factors, and nature and number
of events. Hazard ratios (HRs) and odds ratios with
accompanying 95% conﬁdence intervals, and p values of
univariable and multivariable analysis were extracted. For
multivariable results, the number and nature of variables
(e.g., patient characteristics, laboratory and electrocardio-
graphic ﬁndings, CMR ﬁndings, and treatment) included in
the analysis were recorded. CMR imaging ﬁndings of
interest were left ventricular ejection fraction (LVEF),
WMA at rest or after administration of pharmacological
stress, myocardial perfusion at rest or after administration
of pharmacological stress, early and late microvascular
obstruction (MVO), presence and extent of LGE, presence
of edema, and presence of intramyocardial hemorrhage
(IMH). For each of these imaging ﬁndings, the cutoff that
was used in the paper for deﬁning an imaging result as
positive in the statistical analysis was noted. Outcomes of
interest were hard events (deﬁned as all-cause mortality,
cardiac death, cardiac transplantation, and/or MI), and
major adverse cardiovascular events (MACE). MACE was
Table 1 Description of the Search Strategy Used to Identify Publications of Interest
Population Coronary artery disease OR coronary artery diseases OR CAD OR cardiovascular disease OR cardiovascular diseases OR CVD OR acute
coronary syndrome OR acute coronary syndromes OR ACS OR coronary stenosis OR coronary stenoses OR heart infarction OR heart
infarctions OR (MI NOT mitral insufﬁciency) OR myocardial infarction OR myocardial infarctions OR STEMI OR NSTEMI OR stable angina
OR unstable angina OR angina pectoris OR coronary heart disease OR coronary heart diseases OR chest pain OR heart failure OR
ischemic heart disease OR ischemic heart diseases OR ischemic heart disease OR ischemic heart diseases
Predictive variable Magnetic resonance OR MRI OR CMR OR (MR NOT mitral regurgitation) OR NMR OR perfusion weighted imaging OR (late AND
enhancement) OR LGE OR (delayed AND enhancement) OR late-enhancement OR (late AND enhanced) OR late-enhanced OR MRA
Outcome ([Validat* OR Predict*(Title) OR Rule*] OR [Predict* AND (Outcome* OR Risk* OR Model*)]) OR ([History OR Variable* OR Criteria
OR Scor* OR Characteristic* OR Finding* OR Factor*] AND [Predict* OR Model* OR Decision* OR Identif* OR Prognos*]) OR (Decision*
AND [Model* OR Clinical* OR Logistic Models(MeSH)]) OR (Prognostic AND [History OR Variable* OR Criteria OR Scor* OR Characteristic*
OR Finding* OR Factor* OR Model*]) OR ([risk OR multivariable OR multivariate] AND [association OR associated OR biomarker
OR odds OR marker])
Search results (combined
with AND)
MEDLINE: 3,040
EMBASE: 656
For MEDLINE, “[tiab]” was added to each search term, and for EMBASE, “ti;ab” was added unless indicated otherwise.
ACS ¼ acute coronary syndrome(s); CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance; CVD ¼ cardiovascular disease; LGE ¼ late gadolinium enhancement; MeSH ¼ Medical Subject
Headings; MI ¼ myocardial infarction; MR ¼ magnetic resonance; MRA ¼ magnetic resonance angiography; MRI ¼ magnetic resonance imaging; NMR ¼ nuclear magnetic resonance; NSTEMI ¼ non–ST-
segment elevation myocardial infarction; STEMI ¼ ST-segment elevation myocardial infarction.
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1033deﬁned as any combination of endpoints as deﬁned by the
authors of the original paper, including hard events and
other events such as congestive heart failure, ischemia, un-
stable angina, arrhythmia, stroke, and/or revascularization.
If study data were used in multiple papers (e.g., when
papers referred to the same study or assessed a comparable
number of patients from the same hospital in the same in-
clusion period evaluating the same imaging ﬁndings), we
only included the result of the imaging ﬁnding of the paper
with the largest number of patients. CMR imaging ﬁndings
used for the analysis are listed in Tables 2 and 3. Based on
clinical relevance, we divided the study populations into
2 groups: 1) patients with a recent MI; and 2) patients with
suspected or known CAD (i.e., patients clinically referred
for CMR).Figure 1 Literature Search and Selection Process of Studies Include
Of 3,696 potentially relevant papers, 56 papers met our inclusion criteria and were inclu
magnetic resonance; MI ¼ myocardial infarction.Because there are no criteria established yet to identify
independent prognostic variables in systematic reviews, we
pre-speciﬁed the value of the CMR ﬁndings by categorizing
each feature into 1 of the following 3 groups:
1. Independent prognostic CMR ﬁnding: the prognostic
value of the CMR ﬁnding was assessed in at least
3 studies that included a summed total of >1,000
patients. The summed number of patients included
in studies with a signiﬁcant result on multivariable
analysis was >50% of the total number of evaluated
patients.
2. No independent prognostic CMR ﬁnding: the prog-
nostic value of the imaging ﬁnding was assessed in
at least 3 studies that included a summed total ofd in Systematic Review
ded in the systematic review. CAD ¼ coronary artery disease; CMR ¼ cardiac
Table 2 Study Characteristics: Patients With a Recent MI
Author, Year (Ref. #)
Country (Inclusion Period)
Study Population
Number of
Evaluable Results
(Study Population)
Deﬁnition of CAD
(Time Between MI and MRI),
Days Important Exclusion Criteria
Ahn et al., 2013 (21)
Korea (2007–2010)
135 (167) STEMI
(7 [4–15])
Prior MI or CABG
multivessel intervention
Amabile et al., 2011 (22)
France (2006–2008)
112 (173) STEMI
(4.7  1.9)
Left bundle branch block
Bodi et al., 2010 (23)
Spain (2004–2006)
119 (234) First STEMI
(7  2)
Previous MI, cardiac surgery,
decreased LVEF
Bodi et al., 2009 (24)
Spain (2004–2006)
214 (250) STEMI
(7  1)
Previous MI, cardiac surgery
Bruder et al., 2008 (25)
Germany (2004–2005)
67 (143) STEMI
(4.5  2.5)
d
Cochet et al., 2010 (26)
France (2005–2007)
61 (78) Non-STEMI
(3–7)
Previous MI
Cochet et al., 2009 (27)
France (2001–2005)
184 (190) AMI
(3–7)
d
Eitel et al., 2010 (28)
Germany (nr)
128 (128) STEMI
(3 [2–4])
d
Eitel et al., 2011 (29)
Germany (nr)
202 (267) STEMI
(3 [2–4])
Previous MI
Eitel et al., 2010 (30)
Germany (2006–2008)
208 (267) STEMI
(3 [2–4])
Previous MI/ﬁbrinolysis
Eitel et al., 2011 (31)
Germany (2006–2009)
333 (407) STEMI
(3 [2–4])
Previous MI/ﬁbrinolysis
Grothoff et al., 2012 (32)
Germany (nr)
421 (524) STEMI
(1–4)
d
Husser et al., 2010 (33)
Spain (2001–2009)
192 (231) First STEMI
(8 [6–11])
Cardiac surgery
Husser et al., 2013 (34)
Spain (2001–2010)
304 (335) First STEMI
(6)z
d
Jensen et al., 2010 (35)
Germany (nr)
50 (70) STEMI
(2.9  1.6)
Previous MI, previous
PCI/CABG
Klug et al., 2012 (36)
Austria (2005–2007)
107 (129) STEMI
(2 [2–4])
CHF
Larose et al., 2010 (37)
Canada (nr)
103 (104) STEMI
nr
MI (<6 months),
revas (<6 months)
Lønborg et al., 2013 (38)
Denmark (nr)
199 (287) First STEMI
(2 [1–3])
Previous MI/CABG,
acute stent thrombosis
Lønborg et al., 2013 (39)
Denmark (nr)
309 (505) First STEMI
(90 [80–96])
Previous MI/CABG,
acute stent thrombosis
Miszalski-Jamka et al., 2010 (40)
U.S. (nr)
99 (105) STEMI
(3–5)
Severe pulmonary disease,
CHD, VD, previous PCI/CABG
De Waha et al., 2012 (41)
Germany (nr)
315 (322) STEMI
(3 [2–4])
Previous MI, prior
ﬁbrinolysis
De Waha et al., 2012 (42)
Germany (2006–2008)
423 (512) STEMI
(3 [2–4])
Prior ﬁbrinolysis
De Waha et al., 2010 (43)
Germany (2006–2008)
422 (512) STEMI
(3 [2–4])
Prior ﬁbrinolysis
Prunier et al., 2008 (44)
France (1996–2001)
105 (124) STEMI
(7.8  4.2)
Previous MI
Raman et al., 2010 (45)
Italy (nr)
88 (100) Non-STEMI
(2.1  1.5)
d
Wu et al., 2008 (46)
U.S. (1999–2006)
113 (124) STEMI
(2 [2–4])
Previous MI, revas, AR
Wu et al., 1998 (47)
U.S. (nr)
44 (44) AMI
(10  6)
d
Values are n (N), median (interquartile range), n (%), mean  SD, or range, except as otherwise indicated.C ¼ no overlap with other studies, and the CMR imaging ﬁnding is included in this systematic
review; ◉ ¼ there is overlap with other studies, and the CMR imaging ﬁnding is not included in this systematic review;B ¼ imaging ﬁnding is not described in the paper. *Low dose. y ¼ ﬁxed follow-up
period. zMedian.
ACM ¼ all-cause mortality; AMI ¼ acute myocardial infarction; AR ¼ arrhythmia; As ¼ adenosine; At ¼ atropine; CABG ¼ coronary artery bypass grafting; CHD ¼ congenital heart disease; CHF ¼ congestive
heart failure; CM ¼ cardiac mortality; CMP ¼ cardiomyopathy; CP ¼ chest pain; CT ¼ cardiac transplant; CVA ¼ cerebrovascular accident; Di ¼ dipyridamole; Do ¼ dobutamine; HF ¼ heart failure; HT ¼
hypertension; IMH ¼ intramyocardial hemorrhage; LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; MACE ¼ major adverse cardiovascular event(s); MVO ¼ microvascular obstruction; NA ¼ not
applicable; nr ¼ not reported; NYHA ¼ New York Health Association; OCAD ¼ obstructive coronary artery disease; PCI ¼ percutaneous coronary intervention; PE ¼ pulmonary embolism; revas ¼ revas-
cularization; UA ¼ unstable angina; VD ¼ valvular disease; other abbreviations as in Table 1.
Continued on next page
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CMR Events
MRI Procedure Imaging Characteristics
Follow-Up
Duration,
Months
(SD/Range)
Hard Events,
Deﬁnition
n (%)
MACE,
Deﬁnition
n (%)
Field
Strength, T
Pharm.
Use LVEF WMA Perfusion MVO IS ED IMH
1.5 None B B B B C B B 32 (22–41) d CM, MI, CHF: 12 (9)
1.5 None C B B C B C C 11z (nr) d ACM, CHF, AR,
ACS, revas: 32 (29)
1.5 None ◉ B B B C B B 20 (10–41) d CM, MI, CHF: 18 (15)
1.5 Do* ◉ C B ◉ C B B 18 (9–36) d CM, MI, CHF: 21 (10)
1.5 None C B B C C B B 14  2 d CM, MI, CHF,
UA, revas: 16 (24)
3.0 None B B B C C B B 12y (NA) d CM, MI, UA, CHF: 15 (25)
1.5 None C B B C C B B 12y (NA) d CM, MI, UA, CHF: 44 (24)
1.5 None ◉ B B ◉ ◉ B B 19 (14–21) ACM: 11 (9) ACM, MI, CHF: 17 (13)
1.5 None C B B C ◉ C B 19 (14–21) ACM: 14 (7) ACM, MI, CHF: 33 (16)
1.5 None ◉ B B ◉ ◉ C B 6y (NA) d ACM, MI, CHF: 26 (13)
1.5 None C B B ◉ C B C 6y (NA) d ACM, MI, CHF: 35 (11)
1.5 None C B B C ◉ B B 21 (5–39) ACM 11 (3) ACM, MI, CHF: 73 (17)
1.5 None ◉ B C ◉ C B B 22 (12–42) d CM, MI, CHF: 20 (10)
1.5 None C B B C C C C 32 (11–50) d CM, MI, CHF: 47 (15)
1.5 None ◉ B B B ◉ B B 32  8 ACM MI 6 (12) CM, MI, CHF,
UA, revas: 27 (54)
1.5 None C B B C C B B 53 (45–60) d ACM, MI, CVA, CHF, revas,
ischemia, AF: 63 (59)
1.5 None B B B B C B B 33 (24–42) d ACM, MI, AR, CHF,
LVEF <35: 23 (22)
1.5 None C B B B B B B 28 (24–38) d ACM, MI, HF, CVA: 40 (20)
1.5 None C B B B C B B 27 (22–37) d ACM, HF: 35 (11)
1.5 None C B B C C B B 38  11 d CM, MI, CHF: 41 (41)
1.5 None B B B ◉ ◉ B B 20 (13–29) d ACM, CHF: 37 (12)
1.5 None C B B C C B B 19 (11–27) d ACM, MI, CHF: 69 (16)
1.5 None C B B C C B B 19 (11–27) ACM 25 (6) ACM, MI, CHF: 69 (17)
1.5 None C B B B B B B 49  20 d ACM, MI, CHF: 24 (23)
1.5 None B B B B B C B 6y (NA) d ACM, CHF, AR,
ACS: 16 (18)
1.5 None C B B B C B B 18 (7–23) d CM, MI, CHF: 16 (14)
1.5 None B B B C C B B 16  5 d CM, MI, UA,
CHF, CVA: 19 (43)
Table 2 Continued
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Table 3 Study Characteristics: Patients With Suspected or Known CAD
Author, Year (Ref. #)
Country (Inclusion Period)
Study Population
Number of
Evaluable Results
(Study Population)
Deﬁnition of CAD
(Time Between
MI and MRI)
Important
Exclusion
Criteria
Bello et al., 2011 (48)
U.S. (nr)
100 (100) History of MI, prior PCI/CABG,
signiﬁcant stenosis
VD, CMP, myocarditis, CT,
MI <1 month
Bertaso et al., 2012 (49)
Australia (2008–2009)
362 (362) Clinically referred Prior CABG
Bingham et al., 2011 (50)
U.S. (2002–2006)
908 (1,009) Suspected CAD,
clinically referred
Severe VD
Bodi et al., 2007 (51)
Spain (2003–2006)
420 (420) Clinically referred MI/revas (3 months after CMR)
Bodi et al., 2012 (52)
Spain (2007–2009)
1,722 (1,797) Clinically referred ACS
Buckert et al., 2013 (53)
Germany (2003–2007)
1,152 (1,229) Suspected/progression
of known CAD
Prior MI (<3 months)
Catalano et al., 2012 (54)
Italy (2002–2006)
376 (410) Clinically referred ACS (<6 weeks), HF,
myocarditis, CMP
Charoenpanichkit
et al., 2010 (55)
U.S. (1997–2004)
353 (362) Clinically referred,
measurable LV mass
d
Cheong et al., 2009 (56)
U.S. (2001–2010)
857 (905) Clinically referred CMP, myocarditis,
sarcoidosis
Coelho-Filho et al., 2011 (57)
U.S. (nr)
405 (424) Clinically referred AMI, UA, CHF, CMP,
myocarditis
Di Bella et al., 2013 (58)
Italy (2001–2007)
231 (231) AMI (>3 months) UA, recent ischemia,
VD, HCM, malignancy
Gebker et al., 2011 (59)
Germany (2005–2008)
1,532 (1,699) Chest pain/dyspnea,
suspected/known CAD
UA, myocarditis,
endocarditis, AF
Hundley et al., 2002 (60)
U.S. (1997–1999)
279 (338) Clinically referred,
inconclusive echo
d
Jahnke et al., 2011 (61)
Germany (2001–2008)
679 (717) Chest pain/dyspnea,
suspected/known CAD
d
Jahnke et al., 2007 (62)
Germany (2001–2005)
461 (513) Chest pain/dyspnea,
suspected/known CAD
d
Kelle et al., 2011 (63)
Germany (2000–2004)
1,017 (1,463) Suspected/known CAD,
clinically referred
Early revas
Larose et al., 2007 (64)
U.S. (nr)
147 (153) >30 days after acute MI,
clinically referred
Conditions affecting
RV function
Lo et al., 2011 (65)
Hong Kong (2003–2008)
203 (260) Suspected or known CAD,
clinically referred
Intermediate stenosis,
CMP, myocarditis
Kaminski et al., 2011 (66)
U.S. (nr)
210 (252) HT, clinically referred Previous MI, myocarditis,
VD, NYHA IV
Korosoglou et al., 2010 (67)
Germany (2004–2008)
1,493 (1,784) Suspected or known CAD,
clinically referred
No sinus rhythm, UA, severe
HT, moderate/severe VD
Korosoglou et al., 2011 (68)
Germany (2006–2009)
320 (382) Suspected or known CAD,
clinically referred
No sinus rhythm, UA, severe
HT, moderate/severe VD
Krittayaphong et al., 2009 (69)
Thailand (nr)
2,194 (2,272) 30 yrs of age, clinically
referred
Urgent revas
Krittayaphong et al., 2011 (70)
Thailand (2004–2008)
1,232 (1,232) Suspected or known CAD Previous MI
Krittayaphong et al., 2009 (71)
Thailand (2002–2006)
1,366 (1,418) Suspected or known CAD Q-wave, non-CAD
cardiac disease
Krittayaphong et al., 2010 (72)
Thailand (2002–2007)
1,644 (1,644) 30 yrs of age, HT,
clinically referred
Previous MI, urgent revas
Kwong et al., 2006 (73)
U.S. (nr)
195 (221) Suspected or known CAD,
clinically referred
Previous MI, CMP, UA,
myocarditis, NYHA IV, stenosis,
Kwong et al., 2008 (74)
U.S. (nr)
107 (109) Diabetes mellitus,
clinically referred
Myocarditis, CMP myocarditis,
NYHA IV, stenosis, UA
Steel et al., 2009 (75)
Canada (nr)
254 (264) Clinically referred UA, CHF
Wallace et al., 2009 (76)
U.S. (1997–2004)
221 (266) Clinically referred,
inconclusive echo
Men
Values are n (N), mean  SD, n (%), or median (interquartile range), except as otherwise indicated.C ¼ no overlap with other studies, and the CMR imaging ﬁnding is included in a systematic review;
◉ ¼ there is overlap with other studies, and the CMR imaging ﬁnding is not included in a systematic review; B ¼ imaging ﬁnding is not described in the papers. *High dose. yRange. zMedian.
Abbreviations as in Tables 1 and 2.
Continued on next page
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CMR Events
MRI Procedure Imaging Characteristics
Follow-Up
Duration,
Months
Hard Events,
Deﬁnition
MACE,
Deﬁnition
Field
Strength, T
Pharm.
Use LVEF WMA Perfusion MVO IS ED IMH
1.0
1.5
None C B B B C B B 58  19 ACM: 30 (30) d
1.5 As C B C B C B B 22 (18–25) d CM, MI, revas,
ischemia: 38 (10)
1.5 As C C C B C B B 31  14 CM, MI: 35 (4) ACM, MI, revas: 101 (11)
1.5 Di C C C B C B B 16  10 CM, MI: 23 (5) CM, MI, UA: 41 (10)
1.5 Di B C C B C B B 13  10 CM, MI: 61 (4) d
1.5 As C C C B C B B 50  25 d CM, MI, CVA: 88 (8)
1.0 None B B B B C B B 38  21 d ACM, HF: 56 (15)
1.5 Do* C C B B B B B 72  24 CM, MI: 71 (20) d
1.5 None C B B B C B B 53z (nr) ACM, CT: 252 (29) d
1.5 As/Di C C C B C B B 30 (6–83) CM, MI: 36 (9) d
1.5 None C C B B C B B 38z (nr) d CM, AR: 19 (8)
1.5 Do/At B C B B B B B 25  10 CM, MI: 30 (2) d
1.5 Do,* At ◉ C B B B B B 20 (nr) CM, MI 18 (6)
(ACM): 20 (7)
CHF, UA, revas: 97 (35)
1.5 Do*/As ◉ ◉ C B B B B 57  26 CM, MI: 77 (11) CM, MI, revas: 306 (45)
1.5 Do*/As/At C ◉ ◉ B B B B 27  12 CM, MI: 19 (4) d
1.5 Do,* At C C B B B B B 44  24 CM, MI: 46 (5) ACM, MI, UA, CHF,
AR, revas: 178 (18)
1.5 None C B B B C B B 17 (6–53) ACM: 26 (18) d
NS As C C C B C B B 38  19 CM, MI: 15 (7) d
1.5 None C C B B C B B 19 (6–47) ACM: 21 (10) ACM, MI, UA, CHF: 48 (23)
1.5 Do,* At C C C B B B B 24  12 CM, MI: 53 (4) d
1.5 Do,* At ◉ C B B B B B 28  9 CM, MI: 35 (11) d
1.5 None C B B B C B B 30  19 CM, MI: 92 (4) CM, MI, UA, CHF, AR: 210 (10)
1.5 As ◉ ◉ C B ◉ B B 35  16 CM, MI: 40 (3) CM, MI, UA, CHF: 135 (9)
1.5 None ◉ B B B C B B 31  16 CM, MI: 58 (4) CM, MI, UA, CHF, AR: 157 (11)
1.5 None ◉ C B B ◉ B B 28  18 CM, MI: 62 (4) CM, MI, UA, CHF, AR: 178 (11)
1.5 None ◉ C B B C B B 16 (6–42) CM: 17 (9) CM, MI, UA, CHF, AR: 31 (16)
1.5 None ◉ ◉ B B ◉ B B 17 (6–57)y d ACM, MI, AR,
UA, HF, CVA: 38 (36)
1.5 As/Di C B C B C B B 17 (8–56) CM, MI: 28 (11) CM, MI, UA, revas: 49 (19)
1.5 Do, At ◉ ◉ B B B B B 74  19 CM, MI: 36 (16) ACM, MI, UA, CHF,
revas: 89 (40)
Table 3 Continued
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Table 4 Characteristics of Patients With a Recent MI
First Author
(Ref. #)
Evaluable
Results
(Study
Population)
Age,
Yrs Men
History
of CAD Diabetes HCL Hypertension Smoking
BMI,
(kg/m2)
Ahn et al. (21) 135 (167) 58  12 87 NA 25 27 31 59 nr
Amabile et al. (22) 112 (173) 58  12 83 NA 17 34 38 60 27  1
Bodi et al. (23) 119 (234) 56  11 90 NA 15 39 35 71 nr
Bodi et al. (24) 214 (250) 57  12 84 NA 16 37 41 63 nr
Bruder et al. (25) 67 (143) 61  12 81 NA 21 75 69 43 27  4
Cochet et al. (26) 61 (78) 62  12 77 NA 7 43 36 41 27  4
Cochet et al. (27) 184 (190) 60 (50–72) 77 NA 10 39 36 47 26 (24–29)
Eitel et al. (28) 128 (128) 67 (55–76) 74 NA 23 34 69 37 nr
Eitel et al. (29) 202 (267) 66 (55–74) 70 NA 25 34 67 41 nr
Eitel et al. (30) 208 (267) 66 (55–74) 70 NA 25 34 67 41 nr
Eitel et al. (31) 333 (407) 64 (53–73) 74 NA 23 35 64 41 nr
Grothoff et al. (32) 421 (524) 66  12 76 NA 26 34 69 42 nr
Husser et al. (33) 192 (231) 58  12 82 NA 17 37 41 65 nr
Husser et al. (34) 304 (335) 58  12 80 61 17 38 46 60 nr
Jensen et al. (35) 50 (70) 58  11 82 NA nr nr nr nr 27  5
Klug et al. (36) 107 (129) 57  12 84 NA 8 81 60 56 26  4
Larose et al. (37) 103 (104) 58 (55–60) 77 NA 8 49 34 52 nr
Lønborg et al. (38) 199 (287) 62  11 79 NA 8 49 32 nr nr
Lønborg et al. (39) 309 (505) 61  11 82 NA 7 47 32 nr 27  4
Miszalski-Jamka
et al. (40)
99 (105) 57  11 78 NA 20 92 72 32 28  4
De Waha et al. (41) 315 (322) 65 (54–73) 74 NA 26 37 69 44 28 (25–30)
De Waha et al. (42) 423 (512) 65 (55–73) 75 NA 26 33 68 42 27 (25–30)
De Waha et al. (43) 422 (512) 65 (55–73) 75 NA 26 33 68 42 28 (25–30)
Prunier et al. (44) 105 (124) 59  13 85 NA 12 43 33 62 nr
Raman et al. (45) 88 (100) 59  12 65 NA 43 nr 78 51 29 (26–33)
Wu et al. (46) 113 (124) 57  11 83 NA 17 53 43 52 nr
Wu et al. (47) 44 (44) 58  9 75 NA nr nr nr nr nr
Values are n/N, mean  SD, %, or median (interquartile range).
BMI ¼ body mass index; other abbreviations as in Tables 1 and 2.
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1038>1,000 patients. The summed number of patients
included in the studies with a signiﬁcant result on
multivariable analysis was <50% of the total number
of patients.
3. Not enough evidence to establish the prognostic value
of this ﬁnding: CMR ﬁndings were studied in a
summed total of <1,000 patients and/or <3 studies.
For the ﬁndings that satisﬁed the criteria of an indepen-
dent prognostic CMR ﬁnding, the ranges of adjusted HRs
as reported in the investigated studies are reported. A p value
of <0.05 was considered statistically signiﬁcant.
Results
Search results. Our search yielded 3,040 papers in
MEDLINE and 656 papers in EMBASE. Of these, 3,613
papers were excluded on the basis of title and abstract, and
26 papers on the basis of full-text screening, including 5
papers investigating patients with a low suspicion of CAD
(16–20) (Fig. 1). Reference cross-checking of the selected
papers yielded no additional studies. Of the remaining 56
studies, 27 investigations reported on patients with a recentMI (21–47), and 29 studies reported on patients with sus-
pected or known CAD (48–76). Study characteristics of the
selected papers are listed in Tables 2 and 3 and patient
characteristics in Tables 4 and 5. The total number of
patients included in the studies ranged between 44 and
2,194, with a mean age ranging from 52 to 67 years and a
follow-up duration between 6 and 74 months.
Methodological aspects of the included studies. The
study population, completeness and duration of follow-up,
deﬁnition of prognostic variables, and outcome were clearly
described in most studies (Fig. 2). The results of the indi-
vidual studies are listed in Online Table B. Several issues
concerning the statistical analyses are given in Table 6. First,
31 of the 56 studies (55%) categorized 1 or more continuous
prognostic variables used in the multivariable analysis. Sec-
ond, 4 of the 53 included studies (8%) used previously
published literature to determine the most relevant variables
for subsequent multivariable analysis. Finally, in the majority
of studies, the number of events per variable in multivariable
analyses was <10 (hard events 26 of 27 studies; MACE: 34
of 44 studies), leading to a possible overestimation of the
reported HRs in those studies (77).
Table 5 Characteristics of Patients With Suspected or Known CAD
First Author
(Ref. #)
Evaluable
Results
(Study
Population)
Age,
Yrs Men
History
of CAD Diabetes HCL Hypertension Smoking
BMI
(kg/m2)
Bello et al. (48) 100 (100) 66  11 87 NA 23 67 49 nr nr
Bertaso et al. (49) 362 (362) 62  12 58 43 24 60 58 24 nr
Bingham et al. (50) 908 (1,009) 65 (55–74) 59 49 25 nr 64 6 nr
Bodi et al. (51) 420 (420) 64  11 61 nr 26 44 50 15 nr
Bodi et al. (52) 1,722 (1,797) 64  11 62 nr 28 55 62 22 nr
Buckert et al. (53) 1,152 (1,229) 62  12 72 nr 21 57 63 24 27  4
Catalano et al. (54) 376 (410) 64  11 78 nr 21 57 58 59 26  4
Charoenpanichkit
et al. (55)
353 (362) 64  12 54 nr 36 55 69 42 31  7
Cheong et al. (56) 857 (905) 59  14 66 75 37 12 nr 7 nr
Coelho-Filho et al. (57) 405 (424) 57  14 59 nr 22 57 56 15 28  6
Di Bella et al. (58) 231 (231) 64  11 89 NA 33 52 55 49 26 (24–28)
Gebker et al. (59) 1,532 (1,699) 63  10 67 48 23 74 65 31 28  4
Hundley et al. (60) 279 (338) 63  11 56 nr 37 66 76 59 nr
Jahnke et al. (61) 679 (717) 61  10 69 54 23 74 78 35 27  4
Jahnke et al. (62) 461 (513) 61  9 67 52 19 70 76 43 27  4
Kelle et al. (63) 1,017 (1,463) 61  11 68 52 17 70 73 44 27  4
Larose et al. (64) 147 (153) 63  11 78 NA 37 89 63 33 nr
Lo et al. (65) 203 (260) 62  12 59 16 30 46 70 29 25  4
Kaminski et al. (66) 210 (252) 52  16 59 20 34 65 nr 27 nr
Korosoglou et al. (67) 1,493 (1,784) 65  13 74 55 19 53 71 18 26  4
Korosoglou et al. (68) 320 (382) 64  14 74 nr 22 56 76 22 26  4
Krittayaphong
et al. (69)
2,194 (2,272) 65  11 53 nr 36 65 53 19 24  3
Krittayaphong
et al. (70)
1,232 (1,232) 65  11 48 nr 35 62 63 15 nr
Krittayaphong
et al. (71)
1,366 (1,418) 64  11 55 nr 34 62 49 18 nr
Krittayaphong
et al. (72)
1,644 (1,644) 65  11 48 nr 37 65 NA 17 25  4
Kwong et al. (73) 195 (221) 59  13 68 29 25 56 53 32 29  5
Kwong et al. (74) 107 (109) 59  13 63 nr NA 70 71 23 nr
Steel et al. (75) 254 (264) 58  13 59 nr 25 61 57 11 29  6
Wallace et al. (76) 221 (266) 63  12 0 nr 38 57 73 38 33  8
Values are n (N), mean  SD, %, or median (interquartile range).
Abbreviations as in Tables 1, 2, and 4.
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1039CMR imaging ﬁndings in patients with recent MI. Five
studies analyzed hard events, including 1,223 patients after
ST-segment elevation MI with a total of 67 hard events.
The prognostic value of CMR ﬁndings and cardiovascular
events are shown in Figure 3. None of the CMR ﬁndings
was assessed in more than 1,000 patients. Therefore, no
inference can be made about the prognostic value of CMR
ﬁndings and hard events in patients with a recent MI.
Twenty-seven studies (N ¼ 5,057 patients) analyzed the
association between CMR ﬁndings and MACE (n ¼ 888
events). The independent prognostic value of LVEF,
MVO not otherwise speciﬁed, and presence or extent of
infarct size was studied in more than 1,000 patients and
more than 3 studies. LVEF was an independent predictor
in multivariable analysis of more than 50% of the studies
(group 1). The multivariable HRs of the included studies
ranged between 1.03 and 1.05 per % decrease in LVEF.For the remainder of the CMR ﬁndings, not enough evi-
dence was available to establish independent prognostic
value (group 3). A summary of the results is given in
Table 7. The results of the individual studies are listed in
Online Table A1.
CMR imaging ﬁndings in patients with suspected or
known CAD. Twenty-four studies, comprising 18,212
patients with 958 hard events, studied the association be-
tween CMR ﬁndings and hard events in patients with
suspected or known CAD. Of the CMR ﬁndings that were
studied in more than 1,000 patients and in at least 3 studies,
the presence of inducible WMA, the presence of inducible
perfusion defects, LVEF, and presence of infarct were
important independent predictors of hard events (group 1).
For the presence of inducible WMA, the multivariable HRs
of the included studies ranged between 1.87 and 2.99. As for
the presence of perfusion defects, the reported HRs ranged
Figure 2 Methodological Quality of Included Studies
The methodological quality of the included studies was assessed on 4 domains of potential bias: study population, follow-up, prognostic factor, and outcome. FU ¼ follow-up.
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1040between 3.02 and 3.77. Furthermore, for both of these
CMR ﬁndings, the risk of a hard event increased with the
number of segments involved. For LVEF, HRs ranged be-
tween 0.72 and 0.82 per 10% increase in LVEF. As for the
presence of infarct, the HRs ranged between 2.82 and 9.43.
Eighteen studies (N ¼ 12,847 patients) analyzed the
prognostic value of CMR features for MACE (n ¼ 1,859
events). The independent prognostic value of LVEF, WMA
score, presence of perfusion defects, and presence or extent
of infarct size were studied in more than 1,000 patients and
more than 3 studies. Of these CMR ﬁndings, the presence
of inducible perfusion defects (range of reported HRs was
between 1.76 and 3.21) and presence or extent of infarct size
were independent predictors of MACE in patients with
suspected or known CAD (group 1). A summary of the
results is given in Table 7. The results of the individual
studies are listed in Online Table A2.
Discussion
The results of this systematic review indicate that CMR
features are independent predictors of cardiovascular events
in patients with recent MI as well as in patients with sus-
pected or known CAD. An important ﬁnding is that
different CMR features are associated with events depend-
ing on the patient population under consideration.
This report is among the ﬁrst comprehensive systematic
reviews investigating the independent prognostic value of
different CMR ﬁndings and the risk of future cardiovascular
events. A total of 56 papers with 25,497 patients with recent
MI or suspected or known CAD were included. We found
that most CMR ﬁndings were associated with cardiovascular
events in the univariable analyses. However, because of the
strong associations with established clinical, that is, non-
imaging, cardiovascular prognostic variables, only a few
CMR ﬁndings were independently related to prognostic
events in multivariable analyses.
Patients with recent MI. No independent association was
found between any of the investigated CMR ﬁndings and
hard events (all-cause mortality, cardiac death, cardiactransplantation, and MI), because none of the CMR ﬁnd-
ings was studied in more than 1,000 patients. LVEF was the
only independent predictor independently associated with
MACE. Furthermore, MVO (not otherwise speciﬁed) and
the presence or extent of MI were not independent prog-
nostic CMR ﬁndings in patients with a recent MI. The
other CMR ﬁndings did not meet our criteria for being
considered independently associated (group 3). Although
some of the CMR ﬁndings are promising in patients with
recent MI, most of the ﬁndings were studied in <1,000
patients. More studies including a sufﬁcient number of pa-
tients are required to establish the independent prognostic
value of the results in recent MI patients.
Although LVEF has most often been used to describe left
ventricular function, the prognostic value of LVEF after
myocardial function has been questioned. A low LVEF may
be the result of reduced contractile function due to extensive
myocardial damage, continuing ischemia, or presence of
myocardial stunning. This systematic review showed that
LVEF is 1 of the few CMR ﬁndings that has been widely
studied in patients after recent MI. Although other CMR
ﬁndings may theoretically have more prognostic value than
LVEF, this needs to be established in future studies with
adequate sample sizes.
Histological studies have shown that areas of no-reﬂow
contain capillaries with microthrombi that lead to obstruc-
tion (78). Furthermore, hypoxia in this region of ischemia
causes disruption of the endothelial layer and thereby
extravasation of erythrocytes leading to IMH (79). This
systematic review shows that there is not enough evidence to
support the use of MVO or IMH for prognostication in
patients after a recent MI. Furthermore, the differences
across studies between early and lateMVOmight be explained
by differences in imaging time after ST-segment elevation
MI and time after contrast administration. More uniform
deﬁnition and assessment of MVO are therefore required.
Even though CMR may be used as a diagnostic tool in pa-
tients after a recent MI, current literature does not support the
use of CMR for prognostication. Although CMR is the refer-
ence standard for LVEF, other more readily available and less
Figure 3
Prognostic Value of CMR Findings and Future Cardiovascular Events in Patients With a Recent MI and With
Suspected or Known CAD
(A) In patients with a recent MI, a ﬁnding was deﬁned as an independent prognostic CMR ﬁnding if it was assessed in 3 studies, with a summed total of >1,000 patients,
and the weighted % of studies with a signiﬁcant result on multivariable analysis (number of patients in studies with a signiﬁcant result divided by total number of patients)
of >50%. (B) In patients with suspected or known CAD, a ﬁnding was deﬁned as an independent prognostic CMR ﬁnding if it was assessed in 3 studies, with a summed total
of >1,000 patients, and the weighted % of studies with a signiﬁcant result on multivariable analysis (number of patients in studies with a signiﬁcant result divided by total
number of patients) of >50%. IMH ¼ intramyocardial hemorrhage; LVEF ¼ left ventricular ejection fraction; MVO ¼ microvascular obstruction; NOS ¼ not otherwise speciﬁed;
WMA ¼ wall motion abnormalities; other abbreviations as in Figure 1. * ¼ studies only included the CMR imaging feature in the univariable analysis.
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probably more suitable for this aim in clinical practice (80,81).
Patients with suspected or known CAD. Among patients
with suspected or known CAD, inducible WMA and
inducible perfusion defects were the most important inde-
pendent predictors of hard events. Other independent pre-
dictors were LVEF and infarct size. Furthermore, inducible
perfusion defects and presence/extent of infarct were alsoassociated with MACE. These results indicate that both
inducible WMA and infarct size measurements are impor-
tant in the prediction of future cardiovascular events.
In a recently published meta-analysis, Lipinski et al. (82)
found that a negative stress CMR is associated with a very
low risk of cardiovascular death and MI in patients with
known or suspected CAD. Our systematic review extends
this knowledge by comparing the independent prognostic
Table 6 Statistical Analysis of Included Studies
Analysis method (56 studies)
Treatment of continuous risk predictors
All kept continuous 24 (43)
All categorized/dichotomized 10 (18)
Some categorized, some not 21 (38)
Unclear 1 (2)
Multivariable analysis (53 studies)
Model building strategy
Pre-deﬁned (e.g., based on previous studies or literature) 4 (8)
Stepwise, forward selection, backward elimination 23 (43)
All signiﬁcant in univariable analysis 17 (32)
Unclear 9 (17)
<10 events per predictor used
In studies with hard events as outcome (27 studies) 26 (96)
In studies with MACE as outcome (44 studies) 34 (77)
Small sample size/chance ﬁndings discussed
Sample size sufﬁcient 9 (16)
Small sample size, but chance ﬁnding discussed 19 (34)
Small sample size, chance ﬁnding not discussed 28 (50)
Values are n (%).
MACE ¼ major adverse cardiovascular event(s).
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1042value by evaluation of multivariable analysis of different
CMR ﬁndings. We showed that stress CMR, LVEF, and
infarct size are the most important independent predictors
of cardiovascular events in this patient group.
In current clinical practice, CMR examinations are mainly
performed to guide clinical decision making and not to assess
future risk of patients. If a patient is found to have abnormal
perfusion or WMA, physicians will generally refer them forTable 7 Summary CMR ﬁndings
Independent Prognostic
CMR Finding (Group 1)
Patients with recent MI
Hard events None
MACE LVEF
Patients with suspected
or known CAD
Hard events LVEF
WMA induced (presence/segments)
Perfusion induced (presence/segments)
Infarct size (presence/extent/transmurality)
MACE Perfusion induced (presence)
Infarct size (presence/extent)
NOS ¼ not otherwise speciﬁed; WMA ¼ wall motion abnormality; other abbreviations as in Tables 1 anrevascularization. Although most studies only included late
revascularization, the close relation between CMR results
and revascularization may have introduced bias in the relation
between CMR result and subsequent patient risk because of
the inﬂuence of revascularization in reducing post-CMR
events. Along the same vein, it could have inﬂuenced the
association between CMR result and MACE because of the
inclusion of revascularization in MACE.
Aggregation of studies. Although the primary objective of
this study was to give an overview of the available evidence,
formal pooling of individual studies would have been
problematic for 3 reasons. First, a large difference in clas-
siﬁcation and reporting of CMR ﬁndings was found. Some
of the studies reported investigated variables on a continuous
scale, whereas others used binary divisions and other arbi-
trarily chosen (study-speciﬁc) cutoff values, resulting in
larger HRs compared with studies that used a scale with
multiple points (83). Second, the majority of the studies
included too many variables in their multivariable analysis
for the number of events in the study, leading to “overﬁtting”
and clearly overestimated HRs (84). As a rule of thumb,
models should be developed with 10 to 20 events per variable
(77). In case of a low event rate in a study, variables are best
selected by using predictors established in literature. Third,
the majority of studies reported MACE as a combination of
cardiovascular outcomes. The use of MACE increases the
event rates and statistical power, and captures the overall
prognostic value of the CMR imaging ﬁndings. However,
because MACE included a variety of events with different
importance for patients and clinicians, interpretation ofNo Independent Prognostic
CMR Finding (Group 2)
Not Enough Evidence to Establish
the Prognostic Value (Group 3)
None LVEF
WMA (rest/induced)
Perfusion (rest/induced)
MVO (early/late/NOS)
Infarct size (presence/extent/transmurality)
Edema
IMH
MVO NOS
Infarct size
(presence/extent)
WMA (rest/induced)
Perfusion (rest/induced)
MVO (early/late)
Infarct size (transmurality)
Edema
IMH
WMA rest
(presence/segments)
WMA rest (score)
WMA induced (score)
Perfusion rest
LVEF
WMA rest (score)
WMA rest (presence/segments)
WMA induced
Perfusion rest
Perfusion induced (segments/score)
Infarct size (transmurality)
d 2.
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1043aggregated results is difﬁcult and should be done with care.
A separate analysis on individual component endpoints
could overcome these difﬁculties given that sufﬁcient studies
and events are available.
Although the statistical analyses and reporting varied
across studies, the quality of the individual studies was good.
This makes the studies suitable for a meta-analysis using
individual patient data (IPD). IPD is an analysis that uses
original source data at the patient level and has many ad-
vantages over a meta-analysis of summary results from the
literature, including standardizing statistical analyses, per-
forming adjusted analyses in each study with consistent set
of adjustment variables, and explaining heterogeneity in
prognostic variables across subgroups of patients (85–88).
Recent publications have shown that an IPD is achievable
for prognostic variables (89,90). Several groups are now
compiling a CMR registry, which could fulﬁll an important
need (3).
To better facilitate future prognostic research, we
recommend the development of reporting guidelines for
prognostic studies in cardiovascular imaging. A good
example is the REMARK (REporting recommendations for
tumour MARKer prognostic studies) reporting guidelines in
oncology, which can also be applied to noncancer diseases
(91). Also, the recently published PROGRESS (Prognosis
Research Strategy) recommendations can be translated to
the cardiovascular imaging ﬁeld (92–95).
Conclusions
CMR is capable of providing independent prognostic
information that allows for risk stratiﬁcation in patients
after MI, as well as in patients with suspected or known
CAD.
We showed that in patients with a recent MI, LVEF is
an independent prognostic variable. In patients with sus-
pected or known CAD, the presence of inducible WMA,
inducible perfusion defects, LVEF, and presence of infarc-
tion were independent prognostic variables of CMR
imaging.
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